News blog

Omega Diagnostics

  • BY: Andrew Hore |
  • POSTED: 22/04/2019 |

Allergy and infectious diseases tests developer Omega Diagnostics says that second half trading was slightly better than expected.

Revenues were 28% lower at £9.76m in the year to March 2019 and there was a small second half profit. Like-for-like revenues did improve by 3%. The full year was still loss-making. Net debt was £900,000.

Food intolerance revenues grew but other parts of the business declined.

VISITECT CD4 has achieved the CE Mark and a dossier will be submitted to the expert review panel for diagnostics this month. Approval will enable NGOs to procure the VISITECT CD4 disease test.

© 2020 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds